Maxion Therapeutics Secures £58m Series A with Investment from British Patient Capital
Deal News | Mar 17, 2025 | British Patient Capital
British Patient Capital has announced a £10 million investment in Maxion Therapeutics, as part of a larger £58 million Series A financing round led by General Catalyst. Other participants include Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital, and BGF. Maxion Therapeutics is developing KnotBody-based antibody drugs aimed at diseases linked to ion channel and GPCR dysfunction, such as inflammatory bowel disease and atopic dermatitis. The new funds will be used to bring Maxion's KnotBody technology to clinical proof of concept stage. KnotBody technology combines knottins and antibodies, promising high selectivity and efficacy. Post-funding, key appointments include Elena Viboch from General Catalyst and Emma Johnson from British Patient Capital joining the Maxion board.
Sectors
- Biotechnology
- Pharmaceuticals
- Venture Capital
Geography
- United Kingdom – British Patient Capital is a UK-based investor, and Maxion Therapeutics is a UK-based company.
- Global – The participating investors like Eli Lilly and General Catalyst operate globally, indicating the worldwide interest and impact of the investment.
Industry
- Biotechnology – The article is centered on Maxion Therapeutics, a biotechnology company focused on developing drugs for ion channels and GPCR-related diseases.
- Pharmaceuticals – Maxion's innovative drug development aligns with the pharmaceutical industry, focusing on high-efficacy treatments for inflammatory and other diseases.
- Venture Capital – The article discusses a Series A funding round, showcasing the role of venture capital in financing early-stage biotech innovations.
Financials
- £58 million – The total amount raised in the Series A financing round.
- £10 million – The investment made by British Patient Capital.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Maxion Therapeutics | Target company | Company | A biotechnology company developing KnotBody drugs for ion channel and GPCR-driven diseases. |
| British Patient Capital | Investor | Company | A commercial subsidiary of the British Business Bank investing in Maxion Therapeutics. |
| General Catalyst | Lead Investor | Company | A leading venture capital firm heading the Series A financing round. |
| Solasta Ventures | Investor | Company | A new investment firm participating in the Series A round. |
| Eli Lilly and Company | Investor | Company | A global pharmaceutical company investing in Maxion Therapeutics. |
| LifeArc Ventures | Investor | Company | An existing investor in Maxion Therapeutics supporting the Series A round. |
| Monograph Capital | Investor | Company | An existing investor in Maxion Therapeutics supporting the Series A round. |
| BGF | Investor | Company | An existing investor in Maxion Therapeutics supporting the Series A round. |
| Dr. John McCafferty | Co-founder | Person | Co-founder of Maxion Therapeutics and developer of the KnotBody technology. |
| Dr. Aneesh Karatt-Vellatt | Co-founder | Person | Co-founder of Maxion Therapeutics and developer of the KnotBody technology. |
| Elena Viboch | Board Member | Person | Managing Director at General Catalyst who will join the Maxion Board. |
| Emma Johnson | Board Member | Person | Senior Investment Manager at British Patient Capital who will join the Maxion Board. |
| Arndt Schottelius, MD PhD | Chief Executive Officer | Person | CEO of Maxion Therapeutics. |